At NanoParma™ we believe everyone is important in public health. Thus, we aim to produce a rapid testing system without compromising accuracy of testing. By equipping individuals with the right tools we can improve the safety in communities and help eradicate COVID-19.
The NanoParma™ technology was developed at the National Sun Yat-Sen University of Taiwan, one of the safest countries in the world during the COVID-19 pandemic. The lab where NanoParma™ was developed is the home of many other important medical innovations, and for more than a decade has included the design of tools for infectious diagnosis and cancer detection. Furthermore, NanoParma™ has been the recipient of grants from the Taiwanese government for the purposes of COVID-19 further test development.
Using NanoParma™ proprietary nanoparticles, the detection limit of our rapid testing system has increased by one order (1,000 times), compared to the existing lateral flow type testing technology. The breakthrough of NanoParma™ technology now enables COVID-19 detection with only a single drop of blood or saliva. And, COVID- 19 can be detected in patients with or without symptoms within 20 minutes.